Arkolith/Insider Trading/APRE/Form 4

Hamill John P.

SrVP/CFO/Prin Fin & Acct OfcrAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Mar 14, 2024
Net Buying
Open-Market Buys
$7K
Open-Market Sells
$0
Net Open-Market Flow
$7K
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2024Buy(P)1K$7.29$7K16K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 13, 2024Buy(P)505——505
Mar 13, 2024Buy(P)505——505

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-034673) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML